In this compelling op-ed in MedCity News, David Benshoof Klein, Founder & CEO of Click Therapeutics, explains why it's imperative that digital therapeutics undergo the same rigorous development and validation processes as traditional biotechnological treatments including pre-market development, preclinical refinement, manufacturing process improvement, and dose optimization, followed by thorough clinical validation. Such diligence ensures that digital interventions meet the high standards of quality, safety, and efficacy expected of any new medical therapy. By adopting a biotech-like approach, digital therapeutics can effectively demonstrate their value and reliability in patient care. To explore this perspective further, read the full article in MedCity News.